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The aim of this study was to highlight 
differences in pharmacist’s perceptions regarding use 
of pharmacogenetic information in their professional 
activities based on their practice settings. A survey 
was electronically administered using the Survey 
Monkey to 48 practicing pharmacists in the hospitals 
and non-hospital study groups which include 
community pharmacy and managed care around the 







 Barring minor deviations, there was overall 
homogeneity in our pilot study group’s general 
knowledge, overall confidence in pharmacogenetics 
and perceptions about possible impact of this 
emerging field in their profession, regardless of their 
professional practice environment. Overall low to 
moderate levels of pharmacists’ confidence in 
pharmacogenetics and related areas even a decade 
after completion of Human Genome Project (HGP) 
seems to be a matter of concern. 
 




The completion of the Human Genome 
Project (HGP) has redefined the approach to drugs and 
dosages. Individualized medicine and tailor-made 
drugs is the promise that pharmacogenomics holds for 
patients.1,2Pharmacogenetics testing or testing the 
variation of drug response based on genetic variation 
has been approved by the FDA.1Although, challenges 
still exist in translating these pharmacogenetic tests to 
clinical practice, pharmacists need to be aware of such 
developments in pharmacotherapy. Very soon, in 
addition to tracking drug-drug interactions, 
pharmacists would be required to pay attention to gene 
product-drug interactions as well.3 
 
Managed care pharmacy is also interested in 
pharmacogenetic information based on the accuracy it 
will bring to plan coverage and reimbursement 
decisions.4 According to an article in the Hospital 
Pharmacy, pharmacogenetic information can form the 
basis of drug coverage policy4 that takes into account 
the effectiveness of the drug, the dose and duration of 
use, and length of coverage. In addition, formulary 
decisions can now be more inclusive and prior 
authorization programs will have more information 
than just prescription or claims data.4 
In a recent article in JAPhA, El-Ibiary and 
colleagues see a plethora of opportunities for 
pharmacists to play a vital role in the emerging field of 
pharmacogenetics.5 The three broad areas identified by 
them are: Developing and validating research 
methodologies in pharmacogenetics; establishing the 
role of  pharmacogenetic testing in clinical practice; 
and participation in education and development of 
related technologies.5 
They however, do see a chasm between the 
scope of pharmacogenetics and its clinical application 
and it is up to the pharmacists to fill this void by 
providing services that re-establishes a pharmacist’s 
role in society. 
 
While the impact, scope, and knowledge of 
pharmacogenetics in pharmacists have not been 
evaluated, Sansgiri and Kulkarni6 have looked at 
community pharmacist’s knowledge regarding HGP. 
They found that less than 50% were comfortable in 
their current knowledge regarding the HGP, genetic 
testing and pharmacogenetics. The respondents also 
felt the need for additional training and continuing 
education (CE) credits on human genetics, handling of 








This study highlights differences in 
pharmacists’ (both in the community and in the 
hospital) perceptions of use of “Pharmacogenetic 
information” in their professional activities. In 
addition, this survey determines the need for 
educational and training requirements in 
pharmacogenetics for practicing pharmacists. The 
purpose of this study was to provide an insight 
regarding perceptions of practicing pharmacists in 
Louisville metro area in integrating the concept of 
pharmacogenetics in their professional activities, as 
they are expected to use pharmacogenomics more 
frequently as they provide “Management Medication 
Therapy (MTM)” to their patients.   
 
 
Since its official inception in 2000 (with the 
completion of HGP), ”,pharmacogenetics has made a 
robust impact in the pharmaceutical industry and on 
the process of making drugs.1,2Nearly 25% of the 
marketed drugs have pharmacogenetic labels in their 
inserts and many molecular techniques routinely 
performed in clinical diagnostic laboratories are 
dependent on this concept”1, 2.There is a need to access 
pharmacist’s current level of confidence & knowledge 
in dealing with the challenging concept of 
pharmacogenetics and their perceptions about the 
increased usage of genomic/genetic data in health care 
as well as the social, moral and legal consequences 




In this study tour primary focus was to 
determine and evaluate the differences in pharmacists’ 
perceptions(in Louisville metro area) regarding their 
use of “Pharmacogenetic information” in their 
professional activities based on their practice 
settings.In addition, peripheral objective included 
determination of the need for further educational and 






An analytical study involving cross- 
sectional sample population was conducted to assess 
the study objectives. Figure 1 shows the overview of 
the study design. In this questionnaire in addition to 
demographics, differences in pharmacist’s perceptions 
are being established with references to the use of PGx 
knowledge for professionals in a pharmacy 
setting.Questions were clubbed into three broad 
categories in the survey. The categories include 
(a)general knowledge about the topic (b)ideas about 
pharmacogenetic screening and (c) impact of 
pharmacogenetics on pharmacists (Refer to 
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Pharmacist pool: Hospital, Community, Managed Care
Facilities in Louisville, KY
Surveys sent electronically by Survey Monkey, random sample 
selection 
N*=48; N=32(response rate:: 67%)




To avoid biased results, no operational 
definitions were given for the topics. The panel of 
questions included in the survey was similar to valid 
questionnaires used in human genome projects with 
added modifications to suit the purpose of the study. A 
5-point Likert scale was used to evaluate this portion 
of the questionnaire. Participants indicated their level 
of agreement or disagreement with each of the 
statements, with 1 indicating “strongly disagree”; 2, 
“disagree”; 3, “neutral”; 4, “agree”; 5, “strongly 
agree”. The questionnaire included questions on 
demographic information such as age, gender, race, 
educational background and pharmacy practice 
setting. For determining pharmacists’ overall 
confidence in pharmacogenetics and related fields, a 
4-point modified Likert Scale was used where “high” 
corresponds to 4 and “no clue” refers to a scaled score 
of 1. 
 
The study sample was a pool of pharmacists 
in the Louisville, Kentucky metro area. The 
participating pharmacists were preceptors of the 
Sullivan University College of Pharmacy (SUCOP) 
with their respective affiliated practicing sites whether 
it is Hospitals or Non- Hospital sites that include 
community pharmacies and manage care. The survey 
questionnaire was electronically accessible to all the 
preceptors and was done through the survey monkey.        
Timeline was one (1) month. An electronic 
reminder was sent twice (2x) every 15 days. 
Completed surveys were coded using the preceptor’s 
log in address. The collected responses and 
information are transmitted to SPSS software 19.0 for 
data analysis. Descriptive and inferential statistics 
including Mann Whitney U-test were performed to 






The response rate to demographic portion of 
the survey (Refer to Appendix B) was 67% (32 
responses).Out of the 13% (16) non-responders; 5 
were labeled undeliverable mail; 2 delivered but 
incomplete responses and 9 delivered but no 
responses. Results were obtained from the total of 32 
completed surveys that were returned. Out of the 
respondents, 45% were females and 55% were males. 
The average age of the pharmacists was (44.80±9.60) 
years. Majority (58%) of the respondents had a 
PharmD degree, 40% had a BS degree, while the 
remaining 2% has the above combined degrees. An 
estimated 63% of the respondents worked in hospital 
settings while the remaining 37% worked either in 
community settings or Managed Care Facilities.  









Pharmacist’s knowledge of pharmacogenetics 
 
Pharmacists strongly agreed (4.31± 0.93)* 
with the statement that pharmacogenetics is not just a 
theoretical concept but on the contrary it has 
manifested its potential in several areas of therapeutics 
through targeted drugs and pharmacogenetic testing. 
Furthermore, they strongly concurred (4.03±0.99*) 
with the idea that drug development process will be 
accelerated due to recent advances in 
pharmacogenetics. According to the opinion of 
respondents, drugs developed due to advances in 
pharmacogenetics have benefits of being effectively 
safe (3.61±0.76*), with minimal adverse side reactions 
(3.58±0.96) and increase patient compliance 
(3.19±1.03)*.One of the drawbacks however would be 
its production and manufacturing cost (4.12±1.16)*. It 
was noted that neither practice settings nor awarded 
degrees contributed significance to the differences in 
the opinions of the respondents in this domain. There 
were no statistical significance differences (P>0.05) in 
the responses of the hospital pharmacists when 
compared to that of their colleagues working in the 
community settings or managed care facilities. A 
similar insignificant trend was noted in spite of the 
differences in educational background when 
PharmD’s were compared to those with BS 
pharmacists across all practice settings.  
 
Ideas about pharmacogenetic screening 
 
A frequency distribution of the scores showed that 
most Pharmacists strongly disagreed with the 
statement that pharmacogenetic screening is ethically 
wrong (1.80±1.03)*. The study showed that 
respondents believed that genotyping will reduce 
health care costs(3.23±0.86)* and would allow 
pharmacists some form of service reimbursement for 
genetic counseling (3.77±1.04)*.While everyone 
strongly agreed that there was a need to include 
patient’s geneticinformation in the pharmacy’s 
database in order to improve drug dispensing; the 
majority of the participants however, had some 
reservations regarding health insurers(1.83±1.26)* 
andemployers(1.73±1.26)* gaining free access to a 
patient’s pharmacogenetic profile. It was further 
concurred that health insurers (4.33±0.88)* and 
employers (4.30±0.95)* may discriminate against 
patients if they have access to their genetic profile.    
 
 
The plan to have every pregnant woman 
undergogenetic screening  was met with some 
resistance (2.53±1.33)*.Though favorable, yet there 
were differing opinions (P<0.05) regarding the 
pharmacists’ role with regards to the clinical relevance 
of a PGo/x screening test based on their educational 
credentials (Pharm D versus BS).There were no 
statistical significance differences (P>0.05) in the 
responses of the hospital pharmacists when compared 
to that of their colleagues working in the community 
settings or managed care facilities, for the questions 
corresponding to this section of the survey.  
 
Impact of pharmacogenetics on pharmacists 
 
Hospital pharmacists and their colleagues in 
the community settings and managed care facilities 
agreed that handling of newer drugs will increase the 
operational cost of pharmacies due to its development 
through advances in pharmacogenetics. Additionally, 
in the opinion of both sets of respondents information 
gathered from these genetic advances may be utilized 
for future individualized drug dosing and the patient’s 
therapeutic responses. For the hospital pharmacists, 
the average response score was3.37±1.06 while for the 
non-hospital pharmacists working in community 
settings or managed facilities, it was 
4.18±0.87.Pharmacists in both groups agree that 
education and training are highly recommended for all 
practicing pharmacies and their techs in all types of 
pharmacy practice settings. It is believed that inclusion 
of information regarding pharmacogenetics in the 
curriculum of pharmacy schools (4.48±0.77)* would 
be one measure of keeping future pharmacists abreast 
of knowledge regarding future advances in genetic 
technology. There was a strong support amongst the 
pharmacists to promote avenues for CE in 
pharmacogenetics in various pharmacy schools and 
professional organizations (4.42±0.61)*.Though 
statistically insignificant, both groups agree that 
pharmacogenetics will revolutionize the role of 
pharmacists(3.47±0.91)* and that the pharmacists 
would require to have the patient’s genetic 
information in their database for accurate 
drugdispensing(3.68±0.88)*. 
Subsequently, advance training on proper 
handling of genetically developed drugs would give 
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rapidly changing pharmaceutical way of 
manufacturing drugs.  At the same time, it will 
provide a venue of providers for trainers to train 
upcoming practicing pharmacists.        
Although most pharmacists would have to 
spend more time counseling patients on appropriate 
use of drugs developed as a result of geneticadvances, 
it is believed that the educational training received by 
the pharmacists would allow adequate preparation in 
counseling their respective patients to enhance better 
patient care. Summary of responses from both groups 
in this category showedno statistical significant in 
differences when compared to each other (P>0.05). 
Though pharmacists’ overall confidence in knowledge 
in pharmacogenetics, HGP and genetic testing remains 
LM (low-moderate), yet the difference in summary of 
responses in this category for pharmacogenetics was 
statistically significant for hospital pharmacists 
compared to the non- hospital group (2.70±0.42 versus 
1.6±0.20 with P<0.04). However for the other fields, 






Based on the results, there are no significant 
differences in perceptions of study group of 
pharmacists with regards to their overall knowledge 
on topics related to pharmacogenetics. The use of 
variables like practice site locations, gender, age, race 
and educational degree did not provide any 
statistically significant differences in reference to the 
group’s respective responses to the questionnaires. 
There is however a statistically significant difference 
between the hospital and non-hospital study groups 
response in reference to confidence of knowledge in 
advances in pharmacogenetics. Though the confidence 
level is low for both groups, the hospital pharmacists 
seemed to be relatively more informed about 
pharmacogenetics as compared to the non- hospital 
group. This result seems plausible based on the fact 
that the hospital group might be more aware about the 
effect of polymorphic genes on drug disposition 
probably through a CE program sponsored by the 
clinical setting or through personal efforts (considered 
to be a requirement for offering MTM services.  
 
 Consistent with our findings were those 
reported by ERPEG 6, 8 which states that healthcare 
professionals lack the knowledge and would need to 
be knowledgeable about genetic testing and other 
issues related to human genomics. Pharmacists in our 
study group indicated a low confidence rating that 
warrants the need for more informative education and 
training in this field. Although the number of CE 
programs on pharmacogenomics has shown an 
increase in the recent years, these programs have 
concentrated on general issues.7 More pharmacy 
schools in United States  have started incorporating 
information in pharmacogenomics into their 
curriculum, however, this is far from a universal stand 
point. Only limited numbers of schools have placed 
emphasis on topics pertaining to pharmacogenetics as 
a stand-alone topic.7, 15 
A potentially good resource for the current 
and future pharmacists would be the National Human 
Genome Research Institute (NCHPEG) which was 
established in 1996.The organization establishes 
minimal core competencies in the field of genetics that 
are essential to sharpen skills and confidence of 
pharmacists as they provide patient care. Other 
learning and teaching avenues would include various 
pharmacy conferences that promote continuing 
education programs. This would provide opportunities 
for practicing pharmacists to keep abreast of the 
current trends. Additionally, CE credits may be 
achieved through participation in statewide programs, 
genomic and genetic journal articles, and self-guided 
study. There is definitely a lot of encouragement for 
pharmacy organizations and pharmacy schools to 
include specialized education sessions and workshops 
to broaden the scope of pharmacy practice as it gears 
itself for the future of pharmacy care. The next 
generation of pharmacists could be our current 
Pharmacy technicians. They should also be made 
aware of the advances in pharmacogenetics and how 
this rapidly evolving field could affect their future 
professional role. Colleges of pharmacy and all 
pharmacy organizations should recognize the need for 
CE credit programs and workshops to prepare this 
group. 
 
As new discoveries are made and 
applications developed as a result of advances in 
pharmacogenetics, understanding how it may affect 
our professional responsibilities will be critical. 
Likewise, advances in this field are expected to lead to 
the development of a number of new products that 
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requirements as well as special delivery systems 
.Pharmacists would have to apply the knowledge 
gained through education and training to ensure 
effective delivery of these products. Besides the new 
drugs being developed, pharmacists will also have to 
keep up with the current pharmacogenetic technology 
and understand its applications. The high possibility of 
rapid conversion of many genetic discoveries into 
clinical applications could have prompted the 
pharmacists in our study to believe that they required 
training on the proper handling of upcoming and new 
drugs.  
 
With such advances in pharmacogenomics, 
the pharmacists will have to spend more time 
counseling patients and answering complex questions 
from physicians. This will usher in the era of tailor-
made drugs; drugs that will carry profiles for a 
genetically specific person.9, 10, 11, 12  Statistically 
significant responses were obtained from our study 
group with regards to genetic screening. It was 
strongly agreed that there is “nothing ethically wrong” 
for advocating genetic screening. However, subjecting 
all pregnant women to genetic screening was not at all 
favorable. Further more, genetic profile accessibility 
should be limited to avoid discrepancy in treatment 
and patient rapport due to genetically induced 
discrimination from the employers, insurers and health 
care professionals. With confidence and strong 
conviction, the group believes that the advent of 
genotyping would greatly impact healthcare cost 
(reduction in cost) while subsequently opening 
gateways for reimbursement of pharmacy counseling 
services. Any information gathered from 
pharmacogenetic studies and experiences would be 
beneficial as pharmacists may apply this knowledge to 
customized drug dosing and identify a number of 
patients most likely to respond to drug therapy. 
Moreover, this would help enhance patient counseling 
for specific products. Several medical centers have 
been using genetics as guides to some therapy. It is 
now being used for warfarin and tamoxifen therapy. 
Large and national level laboratories are currently 
offering pharmacogenetic testing.13Everyone in the US 
has access to pharmacogenetic tests not because every 
drug should be tested but rather for drugs with narrow 
therapeutic indexes or for those drugs with significant 
risks of adverse reactions.13According to McLeod2008, 





Certain limitations are adherent to the 
current study.Consideration should be taken into stride 
for accurate interpretation of the study’s significance 
in the perception of the pharmacists’ knowledge in 
reference to the rapidly advancing application of PGo/x 
in pharmacy practice. The responses to the variables 
were subjective and hence open to different 
interpretations. Questionnaires may be perceived 
differently by the subjects due to insufficient 
information and clinical exposure to this new field in 
their practice. The observed outcomes from this would 
be inadequate and a less meaningful insight to the 
subject’s responses. Consequently, a differing opinion 
may occur as pharmacists are given more time to gain 
knowledge on the topics. The subjects were recruited 
using a convenient method of selection by using the 
preceptors affiliated to SUCOP rather than a random 
selection process. The small sample size was limited 
to a specific group of pharmacists thus the results may 
not represent the general perspective of the 
pharmacists at large. Moreover, the study was limited 
to the metro Louisville hospitals, community and 
managed care areas. The time line for completion of 
the questionnaire may be too short to accommodate 
the busy schedules of the participants thereby resulting 
in two incomplete and 11 no-response survey results. 




Hospital pharmacists and their colleagues in 
non-hospital settings have similar perceptionswith 
observed minor deviations in reference to the overall 
influence of pharmacogenetics in their profession. The 
study establishes the fact that the overall confidence in 
knowledge of the pharmacists in pharmacogenetics 
and associated fields can be bestdescribed as low-
moderate (LM). This clearly indicates that there exists 
an insufficient and inadequate learning resource tools 
for the pharmacists. Moreover, factual data points out 
that educational institutes or pharmacy professional 
organizations are lacking in their responsibility to 
educate their colleagues in genomics, which is 
worrisome, given its increasing importance in MTM in 
the coming years. In spite of some recent advances, a 
greater awareness for a more in-depth approach to 
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pharmacy schools of the United States is urgently 
needed. The leadership role of future pharmacists calls 
for a more structured, formalized manner of teaching 
this importantly challenging scientific field. 
Pharmacogenomics and pharmacogenetics may be far 
from being a routine part of clinical and community 
pharmacy practice for some time, however, the field 
presents vast opportunities for involvement in 
personalized medicine, pharmacogenomics research, 
better drug and treatment selection guidelines and 
dosing techniques based on genetic information. All of 
the above leads to improvement in overall patient care. 
As drug experts, pharmacists offer unique perspectives 
on appropriate use and disposition of medications in 
the body and therefore are a natural fit for helping to 







Highlighting Differences In Pharmacists’ 
Perceptions Regarding Use of Pharmacogenetic 
Information in their Profession       
 
This advanced survey is aimed at evaluating 
the perception of practicing pharmacists in 
incorporating the concept of 
“Pharmacogenomics/Pharmacogenetics” in their 
professional activities.  Since its inception in 2001 
(with the completion of Human Genome Project) , 
Pharmacogenomics has made a tremendous impact in 
the pharmaceutical industry and on the process of 
making drugs. Nearly 25% of the marketed drugs have 
Pharmacogenomic labels in their inserts and many 
molecular techniques routinely performed in clinical 
diagnostic laboratories are dependent on “ 
Pharmacogenomics.” Thus, it is absolutely vital that 
practicing pharmacists grasp the basic knowledge of 
“Pharmacogenomics”, since they will be required to 
frequently counsel patients on genomic information as 
they deliver “ Medication Therapy Management”.  
 
Note: Please put a tick mark in the circles 
1,2,3,4 or 5 to indicate your assessment (1 = “strongly 
disagree”; 2=“disagree”; 3 =“neutral”; 4=“agree”; 
5=“strongly agree” ;) 




enetics” studies identifying which gene 
predispose to a disease, do allow the 
scientists to understand crucial biologic 
pathways that can then be directly or 
indirectly targeted with drugs. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
B. I believe that 
“Pharmacogenomics/Pharmacogenetics” is not a 
just a theoretical concept about how information 
from the Human Genome Project (HGP) can be 
used in health care. To the contrary, targeted 
drugs and 
“Pharmacogenomics/Pharmacogenetics” testing 
is a reality today in several areas of therapeutics. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 





C. The drug development process will be 
accelerated with advances in 
“Pharmacogenomics/Pharmacogenetics” due to a 
better understanding of inter-individual variations in 
Pharmacokinetics of certain drugs. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 













D. Drugs developed due to advances in 
“Pharmacogenomics/Pharmacogenetics” will 
have less adverse drug reactions. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
E. Drugs developed due to advances in 
“Pharmacogenomics/Pharmacogenetics” will be 
safer and more efficacious. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
F. Drugs developed due to advances in 
“Pharmacogenomics/Pharmacogenetics” will 
favor patient compliance. 
 
 1.   O   
            2.   O  
 3.   O 
 4.   O 
 5.   O 
 
G. Drugs developed due to advances in 
“Pharmacogenomics/Pharmacogenetics” will 
improve health outcomes. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
IDEAS ABOUT “PHARMACOGENETIC” 
SCREENING: 
  




 1.   O   
                2.   O  
 3.   O 
 4.   O 




B. Genotyping a patient is a reliable method to 
identify or eliminate risk of developing 
congenital diseases. 
 
 1.   O   
                 2.   O  
 3.   O 
 4.   O 
 5.   O 
 
C. To be clinically relevant a 
“Pharmacogenomics/Pharmacogenetics” 
screening test must predict the outcome of drug 
treatment as accurately as possible. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O  
 
D.  Genotyping could be made cost effective if a 
prescriber selects a specific protocol in the 
clinical settings based on the following 
parameters: initial set up costs, fixed cost per 
marker and consumable costs proportional to 
usage. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
E. I believe that “Pharmacogenetic” screening is 
morally and ethically wrong if that information is 
used for making health care decisions. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
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 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
G. Genotyping will reduce cost associated with 
health care. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 




H. Health insurers should have access to a complete 
“Pharmacogenetic” profile for insured members. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
I. Employers should have access to a complete 
“Pharmacogenetic” profile for their employees. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
J. Employers having access to genetic information 
may discriminate against present and potential 
employees. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
K. Health insurers having access to genetic 
information will discriminate against present and 
potential patients. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
L. Pharmacists should be considered providers of 
genetic testing services to patients and should be 
reimbursed for their services. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
 
“PHARMACOGENETICS” AND ITS IMPACTS 
ON PHARMACISTS: 
 
A. The advent of 
“Pharmacogenomics/Pharmacogenetics” will 
revolutionize the role of pharmacists. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
 
B. Pharmacy schools should include information on 
“Pharmacogenomics/Pharmacogenetics” in their 
curricula. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
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C.  Professional Pharmacy Organizations/Pharmacy 
schools should provide continuous education on 
“Pharmacogenomics/Pharmacogenetics” for 
pharmacists. 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
D.  “Pharmacogenomic/Pharmacogenetic” 
information on a patient could directly or 
indirectly improve formulatory management 
decisions in a managed care pharmacy. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 




information available for individual patients 
could potentially make Drug Utilization Review 
(DUR) evaluations and communications more 
robust between the physicians and pharmacists in 
either hospital or managed care settings. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
F.  Pharmacists will need patients’ genetic 
information in their database to improve drug 
dispensing. 
  
 1.   O   
                2.   O  
 3.   O 
 4.   O 






G. Pharmacists as well as pharmacy technicians will 
require additional training on the proper 
handling, storing and dispensing of new drugs 
being developed due to advances in 
“Pharmacogenomics/Pharmacogenetics.” 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
 
H. Drugs being developed due to advances in 
“Pharmacogenomics/Pharmacogenetics” will 
require special storage instructions before 
dispensing. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
 
I. Handing of so called 
“Pharmacogenomics/Pharmacogenetics” drugs 
will increase the operational costs of a pharmacy. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
 5.   O 
 
J. Pharmacists’ workload will increase as they will 
have to spend more time in counseling the 
patients on the appropriate use of 
“Pharmacogenomics/Pharmacogenetic” drugs. 
 
 1.   O   
                2.   O  
 3.   O 
 4.   O 
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K. How do you rate your overall confidence in 
knowledge for " Pharmacogenomics/Pharmogenetics" 
?  
 
 High   
Moderate  
 Low 
 Not a clue 
 
L. How do you rate your overall confidence in 
knowledge for " Human Genome Project" ? 
 High   
Moderate  
 Low 
 Not a clue 
 
M. How do you rate your overall confidence in 
knowledge for " Genetic Testing" ?  
 High   
Moderate  
 Low 





Demographic Analysis       
 
 





A. In which year you were born? 
  
B. What is your gender?   
 
C. Please indicate all the   professional degrees 
(mentioned below) earned? 
 
 1.  BS   
               2.  PharmD 
 3.  Others (specify) 
 
D. In which year did you graduate from the 
PharmacySchool? 
  
E. In which year you were registered as a 
pharmacist? 
 
F.  How many years you have been practicing? 
 
G. What is your ethnicity? 
 
 1.   White, Non Hispanic   
                2.   African American  
 3.   Hispanic 
 4.   Asian 
 5.   Others(Specify) 
 
H. Please indicate your practice settings. 
 
 1.   Chain Pharmacy   
               2.   Independent Pharmacy  
 3.   Hospitals 
                4.    Others (Specify) 
 
I. Which one best describes your principal    
activity at your practice settings? 
 1.  Pharmacy Directors/Managers 
 2.  Clinical Pharmacist 
 3. Staff Pharmacist 
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